|
C3ORF38 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.11870512853329E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.78770001421935E-09 |
| Normal-vs-Stage2 |
5.1516000021401E-08 |
| Normal-vs-Stage3 |
3.41589978525292E-10 |
| Normal-vs-Stage4 |
1.52939994002566E-10 |
| Stage1-vs-Stage2 |
8.758100E-02 |
| Stage1-vs-Stage3 |
5.072300E-02 |
| Stage1-vs-Stage4 |
1.838490E-02 |
| Stage2-vs-Stage3 |
8.141200E-01 |
| Stage2-vs-Stage4 |
6.677800E-01 |
| Stage3-vs-Stage4 |
4.498400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.10349540405741E-11 |
| Normal-vs-AfricanAmerican |
2.36189999999192E-05 |
| Normal-vs-Asian |
4.11610000000673E-05 |
| Caucasian-vs-AfricanAmerican |
7.815600E-01 |
| Caucasian-vs-Asian |
2.721200E-01 |
| AfricanAmerican-vs-Asian |
3.219000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.92259558168462E-11 |
| Normal-vs-Female |
1.79889991791526E-10 |
| Male-vs-Female |
1.698790E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.54670000327573E-08 |
| Normal-vs-Age(41-60Yrs) |
1.08959952171972E-10 |
| Normal-vs-Age(61-80Yrs) |
5.09090547495816E-11 |
| Normal-vs-Age(81-100Yrs) |
3.584200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.174610E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.702230E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.303800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.629400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.793400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.757800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.889600E-01 |
| Classical-VS-Follicular |
1.93470999999557E-05 |
| Classical-VS-Other |
6.445600E-01 |
| Classical-VS-Normal |
8.11870004557846E-09 |
| Tall-VS-Follicular |
9.457500E-02 |
| Tall-VS-Other |
9.823200E-01 |
| Tall-VS-Normal |
1.75420999999343E-05 |
| Follicular-VS-Other |
3.941800E-01 |
| Follicular-VS-Normal |
1.40000233628257E-11 |
| Other-VS-Normal |
1.638310E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.14420029007078E-10 |
| Normal-vs-N1 |
3.02039999677817E-08 |
| N0-vs-N1 |
7.019400E-01 |
|
|
